Tarsus Pharmaceuticals, Inc. 8-K

What Happened

• On January 12, 2026, Tarsus Pharmaceuticals, Inc. announced via Form 8-K that it published a corporate presentation on the Investor & News section of its website. The presentation is included as Exhibit 99.1 to the 8-K. The filing was signed by Bryan Wahl, General Counsel and Corporate Secretary.
• The company states the material is being furnished under Regulation FD and expressly notes the information is “furnished” (not “filed”) for purposes of Section 18 of the Securities Exchange Act and is not automatically incorporated by reference into other filings.

Key Details

• Date of disclosure: January 12, 2026.
• Document posted: Corporate presentation (Exhibit 99.1).
• Location: Investor & News section of Tarsus’ website.
• Regulatory note: Material furnished under Regulation FD; not deemed “filed” for Section 18 liability or incorporation by reference.

Why It Matters

• This is a routine investor-communications disclosure under Regulation FD, not an earnings release or financial results filing; it does not report revenue, quarterly results, or executive changes. Investors should view the presentation on the company website for details and consider it as furnished investor material rather than a formal filed disclosure.